Geron Corporation s trend and data analysis indicates that the stock price has dropped -2.33% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -7.08% . Looking at the past 52 week period, the stock price is down -26.57% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Geron Corporation has a negative value of -29.49 compared to overall market performance.Geron Corporation is having a Relative Strength Index of 46.56 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Geron Corporation (NASDAQ:GERN) has tumbled 0.47% during the past week and has dropped 7.89% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.71%. Geron Corporation (NASDAQ:GERN) has underperformed the index by 8.94% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
For the current week, the company shares have a recommendation consensus of Buy. Geron Corporation (NASDAQ:GERN) : On Friday heightened volatility was witnessed in Geron Corporation (NASDAQ:GERN) which led to swings in the share price. The stock opened for trading at $2.07 and hit $2.13 on the upside , eventually ending the session at $2.1, with a gain of 0.48% or 0.01 points. The heightened volatility saw the trading volume jump to 1,719,232 shares. The 52-week high of the share price is $3.35 and the company has a market cap of $334 million. The 52-week low of the share price is at $1.81 .
Company has reported several Insider transactions to the SEC, on Jun 1, 2015, Melissa Kelly Behrs (EVP BD and Port&Alliance Mgmt) sold 2,380 shares at 3.84 per share price.On Jun 1, 2015, Olivia Kyusuk Bloom (EVP, Chief Financial Officer) sold 2,380 shares at 3.84 per share price.On Mar 19, 2015, Thomas Hofstaetter (director) sold 70,000 shares at 4.10 per share price.
Geron Corporation Last issued its quarterly earnings results on Mar 1, 2017. The company reported $-0.05 EPS for the quarter. Analyst had a consensus estimate of $-0.05. The company had revenue of $.09 million for the quarter, compared to analysts expectations of $.18 million. The companys revenue was down -57.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.05 EPS.
Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.